CN115315436A - 修饰的il-2多肽及其用途 - Google Patents

修饰的il-2多肽及其用途 Download PDF

Info

Publication number
CN115315436A
CN115315436A CN202180020456.2A CN202180020456A CN115315436A CN 115315436 A CN115315436 A CN 115315436A CN 202180020456 A CN202180020456 A CN 202180020456A CN 115315436 A CN115315436 A CN 115315436A
Authority
CN
China
Prior art keywords
modified
polypeptide
polymer
daltons
polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180020456.2A
Other languages
English (en)
Chinese (zh)
Inventor
维杰亚·拉格万·帕塔比拉曼
罗伯托·亚科内
让-菲利普·卡拉洛特
马蒂尔德·阿雷瓦洛-鲁伊斯
杰弗里·威廉·博德
亚历山大·梅维格
弗兰齐·韦贝尔
安娜·海顿
雷吉斯·勃林格
戈尔克姆·库尔图尔杜沙辛
克劳迪娅·费兹
C·德隆
埃里克·阿门塔尼
A·弗洛尔
乔治·奥塔维亚尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mingfeng Treatment Co ltd
Original Assignee
Mingfeng Treatment Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mingfeng Treatment Co ltd filed Critical Mingfeng Treatment Co ltd
Publication of CN115315436A publication Critical patent/CN115315436A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN202180020456.2A 2020-01-10 2021-01-08 修饰的il-2多肽及其用途 Pending CN115315436A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062959382P 2020-01-10 2020-01-10
US62/959,382 2020-01-10
PCT/IB2021/000004 WO2021140416A2 (en) 2020-01-10 2021-01-08 Modified il-2 polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
CN115315436A true CN115315436A (zh) 2022-11-08

Family

ID=74661411

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180020456.2A Pending CN115315436A (zh) 2020-01-10 2021-01-08 修饰的il-2多肽及其用途

Country Status (8)

Country Link
US (2) US11633488B2 (https=)
EP (1) EP4087865A2 (https=)
JP (1) JP2023514010A (https=)
KR (1) KR20220140514A (https=)
CN (1) CN115315436A (https=)
AU (1) AU2021206449A1 (https=)
CA (1) CA3162406A1 (https=)
WO (1) WO2021140416A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019028419A1 (en) 2017-08-03 2019-02-07 Synthorx, Inc. CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES
ES3059360T3 (en) 2018-11-08 2026-03-19 Synthorx Inc Interleukin 10 conjugates and uses thereof
KR20260039812A (ko) 2019-02-06 2026-03-20 신톡스, 인크. Il-2 콘쥬게이트 및 이의 사용 방법
CN114555632A (zh) 2019-08-23 2022-05-27 新索思股份有限公司 Il-15缀合物及其用途
MX2022002740A (es) 2019-09-10 2022-03-25 Synthorx Inc Conjugados de il-2 y metodos de uso para tratar enfermedades autoinmunes.
US11633488B2 (en) 2020-01-10 2023-04-25 Bright Peak Therapeutics Ag Modified IL-2 polypeptides and uses thereof
AR121891A1 (es) 2020-04-22 2022-07-20 Merck Sharp & Dohme CONJUGADOS DE INTERLEUCINA 2 HUMANA SESGADOS AL DÍMERO DEL RECEPTOR DE INTERLEUCINA 2 bgᶜ Y CONJUGADOS CON UN POLÍMERO HIDROSOLUBLE NO PEPTÍDICO
US20230181754A1 (en) 2021-07-09 2023-06-15 Bright Peak Therapeutics Ag Modified checkpoint inhibitors and uses thereof
US20230201365A1 (en) 2021-07-09 2023-06-29 Bright Peak Therapeutics Ag Modified cd20 antibodies and uses thereof
WO2023281479A1 (en) 2021-07-09 2023-01-12 Bright Peak Therapeutics Ag Checkpoint inhibitors conjugated to il-2, and uses thereof
WO2023281485A1 (en) 2021-07-09 2023-01-12 Bright Peak Therapeutics Ag Modified il-2 polypeptides for treatment of inflammatory and autoimmune diseases
US20230201364A1 (en) 2021-07-09 2023-06-29 Bright Peak Therapeutics Ag Antibody conjugates and manufacture thereof
JP2025508823A (ja) 2022-02-23 2025-04-10 ブライト ピーク セラピューティクス エージー 免疫抗原特異的ｉｌ－１８免疫サイトカイン及びその使用
WO2023161857A1 (en) 2022-02-23 2023-08-31 Bright Peak Therapeutics Ag Bifunctional cytokine compositions
WO2024150175A1 (en) 2023-01-11 2024-07-18 Bright Peak Therapeutics Ag Conditionally activated proteins and methods of use
US20240417436A1 (en) * 2023-01-11 2024-12-19 Bright Peak Therapeutics Ag Conditionally activated immunocytokines and methods of use
WO2024150172A1 (en) 2023-01-11 2024-07-18 Bright Peak Therapeutics Ag Cleavable peptides and methods of use thereof
KR20250144433A (ko) * 2023-02-14 2025-10-10 아크론 바이오프로덕츠 엘엘씨 생체내 이용을 위한 인터루킨 제형물

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013205042A1 (en) * 2004-12-22 2013-05-16 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
TW201920241A (zh) * 2017-08-03 2019-06-01 美商新索思股份有限公司 用於增生及感染性疾病治療之細胞激素結合物
WO2019125732A1 (en) * 2017-12-19 2019-06-27 Xencor, Inc. Engineered il-2 fc fusion proteins
CN110520151A (zh) * 2017-01-27 2019-11-29 恩格姆生物制药公司 胰高血糖素受体结合蛋白和其使用方法
WO2019246404A1 (en) * 2018-06-22 2019-12-26 Cugene Inc. Interleukin-2 variants and methods of uses thereof
CN110642934A (zh) * 2019-09-10 2020-01-03 中国医学科学院北京协和医院 靶向调节t细胞的长效白介素-2及其在治疗自身免疫病中的应用
CN114746122A (zh) * 2019-09-10 2022-07-12 新索思股份有限公司 Il-2缀合物和治疗自身免疫性疾病的使用方法
CN116036243A (zh) * 2022-04-20 2023-05-02 北京大学宁波海洋药物研究院 受体偏向的peg化il-2变体组合及其应用

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2019714A1 (en) 1989-06-27 1990-12-27 Richard A. Chizzonite Process for the determination of interleukins
DZ2788A1 (fr) 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
AU5300299A (en) 1998-08-21 2000-03-14 Yeda Research And Development Co. Ltd. Anti-inflammatory peptides derived from il-2 and analogues thereof
HUP0204475A2 (en) 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
US6689353B1 (en) 2000-06-28 2004-02-10 Bayer Pharmaceuticals Corporation Stabilized interleukin 2
DE60129695T2 (de) 2000-06-29 2008-06-05 Merck Patent Gmbh Steigerung von durch antikörper-zytokin-fusionsproteine mediierten immunantworten durch eine kombinierte behandlung mit mitteln zur erhöhung der immunzytokinaufnahme
PT1454138E (pt) 2001-12-04 2012-03-28 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
WO2005007121A2 (en) 2003-07-18 2005-01-27 Massachusetts Institute Of Technology Mutant interleukin-2(il-2) polypeptides
US8147832B2 (en) 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
AU2006207987B2 (en) 2005-01-27 2011-09-15 Novartis Vaccines And Diagnostics Inc. Methods for treating renal cell carcinoma
US7667076B2 (en) 2005-09-14 2010-02-23 Regents Of The University Of California Amide forming chemical ligation
WO2009061853A2 (en) 2007-11-05 2009-05-14 Massachusetts Institute Of Technology Mutant interleukin-2 (il-2) polypeptides
MX2011007647A (es) 2009-01-21 2011-09-01 Amgen Inc Composiciones y metodos para el tratamiento de enfermedades inflamatorias y autoinmunes.
CU23923B1 (es) 2010-11-12 2013-07-31 Ct De Inmunología Molecular Polipéptidos derivados de la il-2 con actividad agonista
ES2866674T3 (es) 2010-11-12 2021-10-19 Nektar Therapeutics Conjugados de una fracción de IL-2 y un polímero
US9428567B2 (en) 2010-12-22 2016-08-30 The Board Of Trustees Of The Leland Stanford Junior University Antagonists of interleukin-2 receptor
HUE029139T2 (hu) 2011-02-10 2017-02-28 Roche Glycart Ag Mutáns interleukin-2 polipeptidek
EP2723380B1 (en) 2011-06-24 2019-08-21 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
US9844582B2 (en) 2012-05-22 2017-12-19 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
EP3004062B1 (en) 2013-05-24 2017-07-19 SynAffix B.V. Substituted azadibenzocyclooctyne compounds and their use in metal-free click reactions
WO2015112016A1 (en) 2014-01-24 2015-07-30 Synaffix B.V. Process for the cycloaddition of a halogenated 1,3-dipole compound with a (hetero)cycloalkyne
KR102042246B1 (ko) 2014-02-06 2019-11-28 에프. 호프만-라 로슈 아게 인터류킨-2 융합 단백질 및 이의 용도
MX385194B (es) 2014-02-21 2025-03-14 Nektar Therapeutics India Pvt Ltd Agonistas il-2rbeta-selectivos en combinación con un anticuerpo anti-ctla-4 o un anticuerpo anti-pd-1.
WO2015164815A1 (en) 2014-04-24 2015-10-29 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
WO2016025385A1 (en) 2014-08-11 2016-02-18 Delinia, Inc. Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases
JP6800141B2 (ja) 2014-08-12 2020-12-16 マサチューセッツ インスティテュート オブ テクノロジー Ｉｌ−２およびインテグリン結合性ｆｃ融合タンパク質による相乗的な腫瘍処置
US20170224777A1 (en) 2014-08-12 2017-08-10 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
MY193723A (en) 2014-08-29 2022-10-27 Hoffmann La Roche Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1
KR102739782B1 (ko) 2015-09-11 2024-12-09 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 생물학적으로 관련된 직교 사이토카인/수용체 쌍
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
US10888603B2 (en) 2016-02-12 2021-01-12 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating cancer cells expressing tumor-associated integrins
JP6911044B2 (ja) 2016-03-16 2021-07-28 シェ、ヤンホイＸｉｅ Ｙａｎｈｕｉ 呼吸器系疾患の治療のためのグルココルチコイドとポリエチレングリコール修飾インターロイキン２の組合せ
KR102687530B1 (ko) 2016-05-04 2024-07-25 암젠 인크 T-조절 세포의 증식을 위한 인터류킨-2 뮤테인
US11395853B2 (en) 2016-06-23 2022-07-26 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Biomimetic drug delivery of an immunomodulatory agent for the treatment of ocular conditions
WO2018002016A1 (en) 2016-06-28 2018-01-04 Ventana Medical Systems, Inc. Application of click chemistry for signal amplification in ihc and ish assays
US11077172B2 (en) 2016-11-08 2021-08-03 Delinia, Inc. IL-2 variants for the treatment of psoriasis
US20190275133A1 (en) 2016-11-10 2019-09-12 Nektar Therapeutics Immunotherapeutic tumor treatment method
CU24483B1 (es) 2016-11-15 2020-04-02 Ct Inmunologia Molecular Método para incrementar los niveles de secreción de la interleucina-2
CN116970059A (zh) 2016-12-22 2023-10-31 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
RU2761377C2 (ru) 2017-04-03 2021-12-07 Ф. Хоффманн-Ля Рош Аг Иммуноконъюгаты антитела к pd-1 с мутантом il-2 или с il-15
KR20190136076A (ko) 2017-04-13 2019-12-09 에프. 호프만-라 로슈 아게 암 치료 방법에 사용하기 위한 인터루킨-2 면역접합체, cd40 작용제 및 임의적인 pd-1 축 결합 길항제
WO2019112852A1 (en) 2017-12-06 2019-06-13 Pandion Therapeutics, Inc. Targeted immunotolerance
JP2020521452A (ja) 2017-05-24 2020-07-27 パンディオン・セラピューティクス・インコーポレイテッド 標的化免疫寛容
AU2018287317B2 (en) 2017-06-19 2024-06-20 Medicenna Therapeutics Inc. Uses and methods for IL-2 superagonists, agonists, and fusions thereof
US20190023760A1 (en) 2017-07-24 2019-01-24 Eth Zurich Method for preparing interleukin-2 or interleukin-2 analogues
EP3668548A2 (en) 2017-08-17 2020-06-24 Nektar Therapeutics Immunotherapeutic tumor treatment method
US20200299349A1 (en) 2017-11-21 2020-09-24 The Board Of Trustees Of The Leland Stanford Junior University Partial agonists of interleukin-2
CN111527109B (zh) 2017-12-26 2024-11-01 南京金斯瑞生物科技有限公司 以抗体Fc区为骨架的融合蛋白二聚体及其应用
WO2019173832A2 (en) 2018-03-09 2019-09-12 AskGene Pharma, Inc. Novel cytokine prodrugs
EA202092489A1 (ru) * 2018-05-21 2021-03-16 Нектар Терапьютикс СЕЛЕКТИВНЫЙ СТИМУЛЯТОР Treg RUR20kD-IL-2 И РОДСТВЕННЫЕ КОМПОЗИЦИИ
HRP20240016T1 (hr) 2018-09-11 2024-03-29 Ambrx, Inc. Konjugati polipeptida interleukina-2 i njihove uporabe
WO2020057646A1 (zh) 2018-09-21 2020-03-26 信达生物制药(苏州)有限公司 新型白介素2及其用途
KR20260039812A (ko) 2019-02-06 2026-03-20 신톡스, 인크. Il-2 콘쥬게이트 및 이의 사용 방법
EP3969051A1 (en) 2019-05-17 2022-03-23 Shenzhen Enduring Biotech, Ltd. Bispecific t-cell engager with cleavable cytokines for targeted immunotherapy
CN114728040A (zh) 2019-06-14 2022-07-08 科优基因公司 新型白介素-2变体及其双功能融合分子
KR20220044534A (ko) 2019-08-13 2022-04-08 엘피스 바이오파마슈티컬즈 조작된 인터류킨-2 수용체 베타 효능제
EP4013777A4 (en) 2019-08-15 2024-01-17 Cytimm Therapeutics, Inc. MODIFIED INTERLEUKIN 2 (IL-2) POLYPEPTIDES, CONJUGATES AND USES THEREOF
CN114555128A (zh) 2019-08-15 2022-05-27 新索思股份有限公司 采用il-2缀合物的免疫肿瘤学组合疗法
MX2022007202A (es) 2019-12-13 2022-10-07 Cugene Inc Fármacos bioactivables a base de citocinas y metodos de uso de los mismos.
US11633488B2 (en) 2020-01-10 2023-04-25 Bright Peak Therapeutics Ag Modified IL-2 polypeptides and uses thereof
AR121891A1 (es) 2020-04-22 2022-07-20 Merck Sharp & Dohme CONJUGADOS DE INTERLEUCINA 2 HUMANA SESGADOS AL DÍMERO DEL RECEPTOR DE INTERLEUCINA 2 bgᶜ Y CONJUGADOS CON UN POLÍMERO HIDROSOLUBLE NO PEPTÍDICO
US20230272001A1 (en) 2020-05-22 2023-08-31 Merck Sharp & Dohme Llc Novel processes for preparing conjugates of the il-2 protein
WO2022140797A1 (en) 2020-12-23 2022-06-30 Immunowake Inc. Immunocytokines and uses thereof
EP4281186A1 (en) 2021-01-22 2023-11-29 Elpis Biopharmaceuticals Anti-pd-l1 monoclonal antibodies and fusion proteins with interleukin-15 (il-15), interleukin-15 receptor 15 alpha or interleukin-2
WO2023281485A1 (en) 2021-07-09 2023-01-12 Bright Peak Therapeutics Ag Modified il-2 polypeptides for treatment of inflammatory and autoimmune diseases
US20230201364A1 (en) 2021-07-09 2023-06-29 Bright Peak Therapeutics Ag Antibody conjugates and manufacture thereof
US20230201365A1 (en) 2021-07-09 2023-06-29 Bright Peak Therapeutics Ag Modified cd20 antibodies and uses thereof
US20230181754A1 (en) 2021-07-09 2023-06-15 Bright Peak Therapeutics Ag Modified checkpoint inhibitors and uses thereof
WO2023281479A1 (en) 2021-07-09 2023-01-12 Bright Peak Therapeutics Ag Checkpoint inhibitors conjugated to il-2, and uses thereof
WO2023161857A1 (en) 2022-02-23 2023-08-31 Bright Peak Therapeutics Ag Bifunctional cytokine compositions
US20240417436A1 (en) 2023-01-11 2024-12-19 Bright Peak Therapeutics Ag Conditionally activated immunocytokines and methods of use
WO2024150175A1 (en) 2023-01-11 2024-07-18 Bright Peak Therapeutics Ag Conditionally activated proteins and methods of use

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013205042A1 (en) * 2004-12-22 2013-05-16 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
CN110520151A (zh) * 2017-01-27 2019-11-29 恩格姆生物制药公司 胰高血糖素受体结合蛋白和其使用方法
TW201920241A (zh) * 2017-08-03 2019-06-01 美商新索思股份有限公司 用於增生及感染性疾病治療之細胞激素結合物
WO2019125732A1 (en) * 2017-12-19 2019-06-27 Xencor, Inc. Engineered il-2 fc fusion proteins
WO2019246404A1 (en) * 2018-06-22 2019-12-26 Cugene Inc. Interleukin-2 variants and methods of uses thereof
CN110642934A (zh) * 2019-09-10 2020-01-03 中国医学科学院北京协和医院 靶向调节t细胞的长效白介素-2及其在治疗自身免疫病中的应用
CN114746122A (zh) * 2019-09-10 2022-07-12 新索思股份有限公司 Il-2缀合物和治疗自身免疫性疾病的使用方法
CN116036243A (zh) * 2022-04-20 2023-05-02 北京大学宁波海洋药物研究院 受体偏向的peg化il-2变体组合及其应用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JEROD L. PTACIN等: "A CD25-biased interleukin-2 for autoimmune therapy engineered via a semi-synthetic organism", 《COMMUNICATIONS MEDICINE》, 26 March 2024 (2024-03-26) *
ONUR BOYMAN等: "Development of a novel class of interleukin-2 immunotherapies for metastatic cancer", 《BIOMEDICAL INTELLIGENCE》, vol. 149, 23 January 2019 (2019-01-23) *
邹险峰等: "聚乙二醇修饰重组人白细胞介素-2纯化及体外理化性质", 《广东技术师范学院学报》, 31 December 2008 (2008-12-31) *
黄丽晶等: "IL-2修饰药物分子研发进展", 《生物工程学报》, vol. 38, no. 9, 31 December 2022 (2022-12-31) *

Also Published As

Publication number Publication date
US20240207417A1 (en) 2024-06-27
AU2021206449A1 (en) 2022-07-21
EP4087865A2 (en) 2022-11-16
US20210252157A1 (en) 2021-08-19
WO2021140416A8 (en) 2022-08-25
JP2023514010A (ja) 2023-04-05
KR20220140514A (ko) 2022-10-18
CA3162406A1 (en) 2021-07-15
WO2021140416A3 (en) 2021-08-19
US12521441B2 (en) 2026-01-13
US11633488B2 (en) 2023-04-25
WO2021140416A2 (en) 2021-07-15

Similar Documents

Publication Publication Date Title
CN115315436A (zh) 修饰的il-2多肽及其用途
US12049520B2 (en) Bicyclic peptide ligands specific for CD137
TWI862640B (zh) 異質雙環肽複合物
KR20200128518A (ko) 다량체성 비사이클릭 펩타이드 리간드
IL300638A (en) Modified IL-18 polypeptides and uses thereof
JP2025508826A (ja) 修飾ｉｌ－１８ポリペプチド
CN113939528B (zh) 增殖免疫细胞的il-2突变体蛋白
JP2024526298A (ja) チェックポイント阻害剤とｉｌ－２とのコンジュゲート、およびその使用
US20230303649A1 (en) Modified il-2 polypeptides for treatment of inflammatory and autoimmune diseases
CN117616036A (zh) 用于治疗炎性疾病和自身免疫性疾病的修饰的il-2多肽
US20250186594A1 (en) Il-18 polypeptides modified with polymers

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination